Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in emerging markets (Brazil, Russia, India, China, Mexico, Turkey, and…

Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France…

Clarivate Epidemiology’s coverage of HD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of HD for each country, as well as…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Huntington’s disease patient populations, covering 171 countries…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

Major depressive disorder (MDD) is a highly drug-treated condition that utilizes an array of drug classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine…

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction, which is characterized by muscle weakness and fatigue. Acetylcholine…

Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. Only a limited number of approved…

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-…

Clarivate Epidemiology’s coverage of postherpetic neuralgia (PHN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

MARKET OUTLOOKPolycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of…

MARKET OUTLOOK Polycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each…